ISSN 2415-3060 (print), ISSN 2522-4972 (online)
  • 30 of 56
Up
УЖМБС 2018, 3(6): 188–192
https://doi.org/10.26693/jmbs03.06.188
Clinical Medicine

Role of Macrophages in the Progression of Papillary Thyroid Carcinoma

Chernenko O. V. 1, Sulaieva O. M. 2, Chuba V. Ya. 2, Ogryzko T. V. 1, Larin O. S. 1
Abstract

Papillary thyroid carcinoma (PTC) is the most common malignant thyroid neoplasia. It is postulated that genetic alterations and tumor antigens can stimulate immune response, orchestrating tumor immune microenvironment. In its turn, immune microenvironment can facilitate cancer progression. It is well known that macrophages are the most important players in tumor development and progression. However, it is still unclear whether there are any relations between number and type of macrophages in progression of papillary thyroid carcinoma. The purpose of this study was to evaluate possible immune-mediated mechanisms of development and progression of papillary thyroid carcinoma, namely estimating the number and type of tumor-associated macrophages and their association with the characteristics of PTC. Material and methods. 60 patients with histopathologically confirmed PTC and 27 patients with follicular adenoma (FA) were enrolled in the study. We considered the tumor size, extra thyroidal extension (ETE), lymphovascular invasion, regional lymph nodes metastases, histological variant of PTC, as well as intensity of inflammatory infiltration and vascularization. To assess tumor associated macrophages and their role in tumor progression immunohistochemical investigation was conducted with the following markers: CD68 to assess the whole set of macrophages and CD163 to evaluate M2-type macrophages. In addition, angiogenesis was considered using VEGF and blood vessels number was evaluated using semi-quantitative score system. Results and discussion. According to the obtained data, PTC was associated with increased number of macrophages, comparing with normal thyroid and follicular adenoma (P<0.0001). Number of macrophages correlated with degree of inflammatory infiltration. These cells were located in tumor and in some cases they were in capsule and around it. In addition, the number of CD163 cells was much higher in patients with invasive growth, demonstrating the possible role of M2 macrophages in PTC progression. Tight relationship was found between the number of M2 macrophages and metastases in the lymph nodes (OR=8.56; 95% CI 2.46-28.22; P=0.0004). Macrophages count was related with high microvascular density (P=0.006), VEGF expression (P<0.0001), intrathyroid invasion (P=0.03) and lymph node dissemination (P=0.005). In addition, the strong correlation between count of CD163+ and MCT+ cells in tumor and lymph nodes was found. We suppose the inflammatory mediated signaling pathways activation in PTC metastasis development. Expression of VEGF was found in tumor cells and in stroma. VEGF expression in tumor cells varied from low to high and correlated with degree of infiltration (r=0.677; P<0.001) and number of M2 macrophages (r=0.812; P<0.0001). In addition there were numerous VEGF positive cells inside infiltrates. Their accumulation around malignant nodules was associated with features of invasion. Conclusions. Thus, increased number of PTC-associated CD163+ macrophages is associated with an increased risk of metastasis to regional lymph nodes due to overexpression of VEGF and tumor cell invasiveness.

Keywords: papillary thyroid carcinoma, metastases, macrophages

Full text: PDF (Ukr) 430K

References
  1. Laryn AS, Cherenko SM, Krushynskaya ZG, Chernenko EV, Sulaeva ON. Sovremennye trendy optymyzatsyy dyagnostyky raka shchytovydnoy zhelezy. Klinichna endokrynologiya ta endokrynna khirurgiya. 2017; 2(58): 19-28. [Russian]
  2. Sulaeva ON, Belemets NY, Seleznev AA, Chuba VYa, Chernenko EV. Morfologycheskaya y molekulyarnaya dyagnostyka opukholey shchytovydnoy zhelezy v sootvetstvyy s mezhdunarodnymy protokolamy y rekomendatsyyamy. Klinichna endokrynologiya ta endokrynna khirurgiya. 2018; 1(61): 7-14. [Russian]
  3. 8th Edition AJCC Cancer Staging Manual. Available from: https://cancerstaging.org/CSE/general/Pages/articles.aspx
  4. Can NY, Ayturk S, Celik M, Sezer YA, Ozyilmaz F, Tastekin E, et al. Histological perspective on the effects of tumor-associated macrophages in the tumor microenvironment surrounding papillary thyroid carcinoma. Pol J Pathol. 2016; 67(4): 332-44. https://doi.org/10.5114/pjp.2016.65865.
  5. Galli F, Iodice V, Lauri C, Signore A. New approaches to image thyroid cancer cells and microenvironment. Q J Nucl Med Mol Imaging. 2015; 59(2): 184-96. https://www.ncbi.nlm.nih.gov/pubmed/25737425
  6. Herrmann G, Schumm-Draeger PM, Muller C, Atai E, Wenzel B, Fabian T, et al. T lymphocytes, CD68-positive cells and vascularisation in thyroid carcinomas. J Cancer Res Clin Oncol. 1994; 120(11): 651-6. https://www.ncbi.nlm.nih.gov/pubmed/7525593. https://doi.org/10.1007/BF01245376
  7. Ivanova K, Manolova I, Ignatova MM, Gulubova M. Immunohistochemical Expression of TGF-Β1, SMAD4, SMAD7, TGFβRII and CD68-Positive TAM Densities in Papillary Thyroid Cancer. Open Access Maced J Med Sci. 2018; 6(3): 435-41. https://www.ncbi.nlm.nih.gov/pubmed/29610597. https://www.ncbi.nlm.nih.gov/pmc/articles/5874362. https://doi.org/10.3889/oamjms.2018.105.
  8. Kim TH, Kim YN, Kim HI, Park SY, Choe JH, Kim JH, et al. Prognostic value of the eighth edition AJCC TNM classification for differentiated thyroid carcinoma. Oral Oncol. 2017; 71: 81-6. https://www.ncbi.nlm.nih.gov/pubmed/28688696. https://doi.org/10.1016/j.oraloncology.2017.06.004
  9. Miyauchi A, Ito Y, Oda H. Insights into the Management of Papillary Carcinoma of the Thyroid. Thyroid. 2018; 28(1): 23-31. https://www.ncbi.nlm.nih.gov/pubmed/28629253. https://www.ncbi.nlm.nih.gov/pmc/articles/5770127. https://doi.org/10.1089/thy.2017.0227
  10. Pusztaszeri MP, Faquin WC, Sadow PM. Tumor-Associated Inflammatory Cells in Thyroid Carcinomas. Surg Pathol Clin. 2014; 7(4): 501-14. https://www.ncbi.nlm.nih.gov/pubmed/26837551. https://doi.org/10.1016/j.path.2014.08.006.
  11. Qing W, Fang WY, Ye L, Shen LY, Zhang XF, Fei XC, et al. Density of tumor-associated macrophages correlates with lymph node metastasis in papillary thyroid carcinoma. Thyroid. 2012; 22(9): 905-10. https://www.ncbi.nlm.nih.gov/pubmed/22870901. https://www.ncbi.nlm.nih.gov/pmc/articles/3429273. https://doi.org/10.1089/thy.2011.0452.
  12. Ryder M, Ghossein RA, Ricarte-Filho JC, Knauf JA, Fagin JA. Increased density of tumor-associated macrophages is associated with decreased survival in advanced thyroid cancer. Endocr Relat Cancer. 2008; 15(4): 1069-74. https://www.ncbi.nlm.nih.gov/pubmed/18719091. https://www.ncbi.nlm.nih.gov/pmc/articles/2648614. https://doi.org/10.1677/ERC-08-0036.
  13. Sulaieva ON, Chernenko OV. Correlations between tsh level and morphological features of thyroid tumours. European Thyroid Journal. 2017; 6: 85-6.
  14. Szebeni GJ, Vizler C, Kitajka K, Puskas LG. Inflammation and Cancer: Extra- and Intracellular Determinants of Tumor-Associated Macrophages as Tumor Promoters. Mediators Inflamm. 2017; 2017: 9294018. https://www.ncbi.nlm.nih.gov/pubmed/28197019. https://www.ncbi.nlm.nih.gov/pmc/articles/5286482. https://doi.org/10.1155/2017/9294018.